Bloomberg News

Siga Shouldn’t Have to Pay PharmAthene Over Drug, Lawyer Says

January 10, 2013

Siga Technologies Inc. (SIGA:US) shouldn’t have to hand over 50 percent of the profits from a smallpox medicine to rival PharmAthene Inc. (PIP:US), lawyers for the drugmaker told an appeals court today.

To contact the reporter on this story: Phil Milford in Wilmington, Delaware at pmilford@bloomberg.net

To contact the editor responsible for this story: Andrew Dunn at adunn8@bloomberg.net


Burger King's Young Buns
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Companies Mentioned

  • SIGA
    (SIGA Technologies Inc)
    • $2.66 USD
    • -0.01
    • -0.38%
  • PIP
    (PharmAthene Inc)
    • $1.29 USD
    • -0.05
    • -3.88%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus